NCT06603766View on ClinicalTrials.gov

Treatment of Persistent Pulmonary Hypertension in Neonates With Nebulized Magnesium Sulfate

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

September 28, 2023

Study Completion Date

September 28, 2023

Conditions
Magnesium Sulfate - PPHN
Interventions
DRUG

IV Magnesium Sulfate

MgSO₄'s mechanism in PPHN includes activating cellular processes, modulating membrane excitability, and acting as a physiological calcium antagonist. It exerts sedative, muscle relaxant, and bronchodilatory properties, while concurrently inducing a state of alkalosis.

DRUG

Inhalational magnesium sulfate

It gives us the same mechanism of action as IV MgSO4 with less side effects.

Trial Locations (1)

Unknown

Pediatrics Department, Faculty of Medicine, Benha University., Benha, Egypt.

All Listed Sponsors
lead

Benha University

OTHER

NCT06603766 - Treatment of Persistent Pulmonary Hypertension in Neonates With Nebulized Magnesium Sulfate | Biotech Hunter | Biotech Hunter